Mechanisms of Resistance to Cabazitaxel

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 193-201

  Duran, George E ^a   Wang, Yan C ^a   Brian Francisco, E ^a   Rose, John C ^a   Martinez, Francisco J ^a   Coller, John ^a   Brassard, Diana ^b   Vrignaud, Patricia ^b   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CABAZITAXEL; CISPLATIN; CLASS III BETA TUBULIN; COLCHICINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA GROUP F PROTEIN; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN E; LIVIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RHODAMINE 123; RNA; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; VALSPODAR; VIMENTIN; VINBLASTINE; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; CYCLOSPORIN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; TAXOID; TUBB1 PROTEIN, HUMAN; TUBULIN;

ACCUMULATION ASSAY; APOPTOSIS; ARTICLE; CELL PROLIFERATION ASSAY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; MCF 7 CELL LINE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUBULIN POLYMERIZATION ASSAY; WESTERN BLOTTING; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOSPORINS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; P-GLYCOPROTEINS; TAXOIDS; TUBULIN;

EID: 84921284750     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0155     Document Type: Article

References (48)

1. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61.
2. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 2006;45:365-74.
3. Schaner ME, Ross D, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86.
4. Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther 2010;9:2970-81.
5. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcomamutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 1996;56:1091-7.
6. Jaffrezou J-P, Dumontet C, Derry W, Duran G, Chen G, Tsuchiya E, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 1995;7:517-27.
7. Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013;19:2973-83.
8. Sanofi. Jevtana (cabazitaxel) injection. Summary of product characteristics, EMA, WC500104764, 2014. http://www.ema.europa.eu/ema/.
9. Sanofi. Jevtana (cabazitaxel) injection. Prescribing information, FDA, 201023, 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
10. Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, et al. Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2013;7:1-12.
11. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line, MES-SA. Cancer Res 1985;45:4091-96.
12. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25.
13. Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
14. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991;266:3987-94.
15. Duran GE, Wang YC, Francisco EB, Yu RX, Sikic BI. Identification of genes associated with non-MDR1 taxane resistance in human ovarian carcinoma cell lines by microarray analysis [abstract]. In: Proceedings of the 94th Annual Meeting of the American Association for Cancer Research; 2003 July 11-14; Washington, DC: AACR; 2003. Abstract nr 5760.
16. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997;11:253-7.
17. Zapata JM, Krajewska M, Krajewski S, Huang R-P, Takayama S, Wang H-G, et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 1998;47:129-40.
18. Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillardt MR, et al. Let-7modulates acquired resistance of ovarian cancer to Taxanes via IMP-1- mediated stabilization of MDR1. Int J Cancer 2012;130:1787-97.
19. Malofeeva EV, Domanitskaya N, Gudima M, Hopper-Borge EA. Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res 2012;72:6457-67.
20. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116:824-9.
21. Kavallaris M, Kuo DY-S, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of speci fi c beta tubulin isotypes. J Clin Invest 1997;100:1282-93.
22. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
23. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 2001;98:11737-42.
24. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III betatubulin reducesmicrotubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.
25. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 2005;65:2397-405.
26. Ganguly A, Yang H, Cabral F. Class III beta-tubulin counteracts the ability of paclitaxel to inhibit cell migration. Oncotarget 2011;2:368-77.
27. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.
28. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer. Cancer Res 2007;67:9356-63.
29. Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, et al. Neuronalassociated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. Mol Cancer Ther 2004;3:1137-46.
30. Blade K, Menick D, Cabral F. Overexpression of class I, II or IVb β-tubulin isotypes in CHO cells is insuffi cient to confer resistance to paclitaxel. J Cell Sci 1999;112:2213-21.
31. Ranganathan S, McCauley R, Dexter D, Hudes G. Modulation of endogenous β-tubulin isotype expression as a result of human βIII cDNA transfection into prostate carcinoma cells. Br J Cancer 2001;85:735-40.
32. Nicoletti M, Valoti G, Giannakakou P, Zhan Z, Kim J-H, Lucchini V, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCIanticancer drug screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001;7:2912-22.
33. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003;9:2992-7.
34. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
35. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:E25-30.
36. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
37. Hetland TE, Hellesylt E, Florenes VA, Trope C, Davidson B, Kaern J. Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 2011;42:1019-26.
38. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapyinduced apoptosis. Cancer Res 2003;63:6221-8.
39. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spndle checkpoint and confers paclitaxel resistance. Cell Cycle 2006;5:1001-7.
40. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-606.
41. Mullan PB, Quinn PE, Gilmore PM, McWilliams S, Andrews H, Gervin C, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-31.
42. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GKF, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413-20.
43. Sung M, Giannakakou P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 2014;33:1418-28.
44. Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, et al. Loss of BRCA1 expressionmay predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006;26:695-702.
45. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479-87.
46. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Cancer 2007;31:277-83.
47. Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 2011;65:40-5.
48. Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X, et al. Acquisition of epithelial- mesenchymal transition is associated with Skp2 expression in paclitaxelresistant breast cancer cells. Br J Cancer 2014;110:1958-67.